Form D · Biotechnology
Advanced Proteome Therapeutics CORP
Burnaby, A1 · CIK 0001040368
Offering snapshot reported May 26, 2020 · SEC filing
- Reported sold
- $127K Offering amount: $342K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 19, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2020 | Initial | $127,151 | No comparison | 3 | SEC filing |
| Sep 4, 2018 | Initial | $15,365 | No comparison | 1 | SEC filing |
| Nov 3, 2016 | Initial | $97,500 | No comparison | 2 | SEC filing |
| May 25, 2016 | Initial | $217,406 | No comparison | 23 | SEC filing |
| Feb 28, 2013 | Initial | $160,050 | No comparison | 5 | SEC filing |
| Feb 14, 2013 | Initial | $690,000 | No comparison | 39 | SEC filing |
| Sep 11, 2012 | Initial | $292,900 | No comparison | 8 | SEC filing |
| Mar 2, 2012 | Initial | $35,000 | No comparison | 6 | SEC filing |
| Nov 8, 2010 | Initial | $900,000 | No comparison | 24 | SEC filing |
| Nov 2, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 8, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-367643
The additional USD$215,135 may be received upon the exercise of warrants sold inside and outside the U.S. US dollar amounts are based on the Bank of Canada noon rate of exchange on May 19/20, CAD$1.3898 = US$1; and May 22/20, CAD$1.4015 = USD$1.
Each unit consists of 1 common share and 1 transferable share purchase warrant. Each warrant is exercisable at a price of CAD$0.10 per share for 2 years.
Source: Form D, filed May 26, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jean Bellin | Director |
| Ben Catalano | Director |
| Randal Chase | Director |
| William John (Bill) Dickie | Director, Executive |
| John Garrett | Director |
| Gary Hayes | Director |
| Edward Kelly Hyslop | Director |
| Alexander (Allen) Krantz | Director, Executive |
| Alexander Krantz | Director, Executive |
| Allen Krantz | Director, Executive |
| Ken Phillippe | Executive |
| Kenneth Phillippe | Executive |
| Paul Woodward | Director, Executive |
| Martin Woodward | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
104 8337 Eastlake Drive
Burnaby, A1, V5A 4W2
Burnaby, A1, V5A 4W2